Literature DB >> 8136893

Heparan sulfate expression patterns in the amyloid deposits of patients with Alzheimer's and Lewy body type dementia.

D Van Gool1, G David, M Lammens, F Baro, R Dom.   

Abstract

Heparan sulfate (HS), along with serum amyloid P component, has been identified in all types of amyloid investigated so far, regardless of the type of amyloid protein deposited. To assess whether unique or specific HS proteoglycans (HSPGs) may be involved in the formation of these lesions, we have investigated the accumulation of several distinct HSPG epitopes in the cerebra of patients with different forms of neurodegenerative disease. A panel composed of several antibodies revealed distinctive patterns of HSPG accumulation. In patients with dementia of the Lewy body type, the burned-out-type plaques and preamyloid-type plaques were strongly stained by both the anti-HS 'chain' and anti-HS 'stub' antibodies, but by none of the available anti-core protein antibodies. In Alzheimer's disease, the preamyloid-type plaques, dense-cored-type plaques, neuritic-type plaques and the neurofibrillary tangles were stained by the anti-'stub' antibody. The anti-'chain' and the anti-core protein antibodies, in contrast, failed to stain the preamyloid-type plaques and burned-out-type plaques, but stained the neuritic-type plaques in these patients. These data suggest differences in the types of HS and HSPG (fragments) that accumulate in amyloid lesions that may hallmark neurodegenerative disorders of different etiologies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8136893     DOI: 10.1159/000107338

Source DB:  PubMed          Journal:  Dementia        ISSN: 1013-7424


  7 in total

1.  Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain.

Authors:  M M Verbeek; I Otte-Höller; J van den Born; L P van den Heuvel; G David; P Wesseling; R M de Waal
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Glycosaminoglycans have variable effects on α-synuclein aggregation and differentially affect the activities of the resulting amyloid fibrils.

Authors:  Surabhi Mehra; Dhiman Ghosh; Rakesh Kumar; Mrityunjoy Mondal; Laxmikant G Gadhe; Subhadeep Das; Arunagiri Anoop; Narendra N Jha; Reeba S Jacob; Debdeep Chatterjee; Soumik Ray; Nitu Singh; Ashutosh Kumar; Samir K Maji
Journal:  J Biol Chem       Date:  2018-06-29       Impact factor: 5.157

3.  Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells.

Authors:  Paul O'Callaghan; Elina Sandwall; Jin-Ping Li; Hong Yu; Rivka Ravid; Zhi-Zhong Guan; Toin H van Kuppevelt; Lars N G Nilsson; Martin Ingelsson; Bradley T Hyman; Hannu Kalimo; Ulf Lindahl; Lars Lannfelt; Xiao Zhang
Journal:  Brain Pathol       Date:  2008-04-11       Impact factor: 6.508

Review 4.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

5.  Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease.

Authors:  Chia-Chen Liu; Na Zhao; Yu Yamaguchi; John R Cirrito; Takahisa Kanekiyo; David M Holtzman; Guojun Bu
Journal:  Sci Transl Med       Date:  2016-03-30       Impact factor: 17.956

6.  Contribution of syndecans to cellular internalization and fibrillation of amyloid-β(1-42).

Authors:  Tamás Letoha; Anett Hudák; Erzsébet Kusz; Aladár Pettkó-Szandtner; Ildikó Domonkos; Katalin Jósvay; Martin Hofmann-Apitius; László Szilák
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

7.  Syndecan-3 as a Novel Biomarker in Alzheimer's Disease.

Authors:  Anett Hudák; Annamária Letoha; Csaba Vizler; Tamás Letoha
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.